Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis

Table 1 Characteristics of selected studies for Meta-analysis

Study	Trial design	No. of patients	No. of patients		Intervention		Mean age (years)
Study	Trial design	No. of patients	therapy group1	Control group	therapy group	Control group	therapy	Control group
Iacovelli et al. (2014). Italy	RCT	89	65	24	Everulimus second line	Temsirolimus second line	60.3	58.2
Alimohamed et al. (2014). Canada	RCT	245	115	130	Everulimus second line	Temsirolimus second line	59	59
Wong et al. (2014). USA	RCT	401	223	178	Everulimus second line	Temsirolimus second line	64	63
Harrison et al. (2013). USA	RCT	56	19	37	Everulimus second line	Temsirolimus second line	64.3	61.8
Chen et al. (2012). USA	RCT	192	117	75	Everulimus second line	Temsirolimus second line	62	62.9
Patel et al. (2016). USA	RCT	90	59	31	Everulimus second line	Temsirolimus second line	61.6	59.6
Motzer et al. (2015). USA	RCT	101	50	51	Everulimus	Everolimus plus Lenvatinib	59	61

ISSN: 1478-7547